LETTER FROM THE CHIEF

I am so proud of our Division this quarter, it is hard to know where to start! First, a warm welcome to Dr. Michel Mendler who has recently joined our Division as a transplant hepatologist and a Clinical Professor of Medicine. Dr. Mendler will enable an expansion of our hepatology outreach practice to Las Vegas, Rancho Mirage, Inland Empire (Corona) and beyond, and will bolster our transplant program in San Diego and our clinical research activities in hepatology. Second, we are moving! Read about our new administrative and clinical research space on the Thornton Hospital campus in La Jolla. Third, Dr. Thomas Savides has reviewed the current state of our Advanced Endoscopy Center at UCSD, please turn to page 3 for more information. This center continues to advance the newest techniques in interventional endoscopy, and is a great resource to our community. Thanks so much to Drs. Savides, Abbas Fehmi, and Mary Lee Krinsky for their tireless efforts in making this center such a success, and for setting an example for those of us building centers of excellence in IBD, celiac disease, liver disease, and motility disorders. Fourth, our research faculty have had spectacular success with obtaining NIH grant funding. I am thrilled to report that Drs. Ravi Mittal, John Chang, and Bernd Schnabl received NIH R01 and/or Director’s Awards this quarter. Fifth, many of our clinical faculty have recently received the US News and World Report and Castle Connolly 2011 designation of Americas Top Doctors—The Best in American Medicine, and/or the San Diego Medical Society designation as a Top Doctor in San Diego, including Robert Gish, Thomas Savides, Ravinder Mittal, and William Sandborn. In addition, our Division will have a strong presence at the American College of Gastroenterology annual meeting in late October, where faculty members will make multiple symposium and abstract presentations. We also continue a robust output of publications in the medical literature, with over 40 new publications this quarter.

Finally, I want to speak about change. With the incredible growth that the Division has experienced this year comes change. Everything is changing, and it seems like all at once. We are moving, shuffling labs and offices to accommodate new faculty, re-engineering every aspect of our clinical practice, from the clinics, to the endoscopy unit, to the hospital consult service, and we are expanding our outreach activities. This period of change is exciting, but it is also hard. We are asking a lot of everyone, from the nurses, endoscopy technicians, schedulers, medical assistants, and administrative assistants, from the administrators of the clinics and endoscopy units, from the Division administrator, from the GI fellows, and from the physician and scientist faculty members. The changes we are making will improve the care of our patients, help us train better doctors, and enable scientific discoveries. And I must say, the universal willingness to change and make things better is inspirational. Together we are in the early stages of transforming the Division from something good to something great! A big Thank You to everyone for stepping up and doing your part. I can’t imagine a better group of people to do this with.
We’d like to welcome Dr. Michel Mendler to our division, he is our newest faculty recruit, his clinical focus will be general and transplant hepatology. Dr. Mendler is originally from San Francisco, but spent part of his childhood in Santa Monica and France. With a B.S. degree from the University of California, Los Angeles, Dr. Mendler returned to France in pursuit of a medical career. In 1992, Dr. Mendler graduated from the University of Rennes Medical School, where he went on to complete his residency in Internal Medicine before finishing off fellowships in GI and hepatology at the Limoges University Hospital. His professional career includes appointments at France’s Rennes University Hospital, the GI Division at University of Southern California and most recently Loma Linda University Medical Center. Dr. Mendler’s research interest primarily focus on clinical; some translational: hepatic iron overload, complications of portal hypertension, post-transplant immune response and HCV outcomes; alcoholic liver disease, and HCC. Among his career highlights is an NIDDK R21 grant to study SAMe in alcoholic hepatitis, he is currently working on developing a point of care test for spontaneous bacterial peritonitis as well as new web-based assessment of minimal hepatic encephalopathy.

**2011 American College of Gastroenterology—Annual Meeting**

Please support our GI Fellows as they enter the final round of ACG GI Jeopardy, the final round will be Saturday, October 29, 2011 @ 5:15pm Maryland Ballroom. **Drs. Suresh Pola, Thuy Anh Le and Imad Elkhatib** scored in the Top 5% out of 104 GI Programs. In this final round they will be competing against: Cleveland Clinic, Jackson Memorial Hospital (University of Miami), Walter Reed, and University of California, San Francisco.

This is the first time a team from UCSD has made it through to the finals. We wish our Fellows the best of luck!

You may find more information on our presence at this year’s ACG meeting in the supplemental insert at the end of this newsletter.
The UCSD Advanced Endoscopy was established in 1993 and continues to be a local, regional, and national leader in GI endoscopic care and research. The program has been on the leading edge of new endoscopic technologies, being the first in San Diego to introduce Endoscopic Ultrasound (EUS), double balloon enteroscopy, and endoscopic treatment of dysplastic Barrett’s esophagus/early esophageal cancer with radiofrequency ablation, cryotherapy, and endoscopic mucosal resection.

The clinical team is directed by Dr. Thomas Savides, M.D., Professor of Clinical Medicine, and includes Syed Abbas Fehmi, M.D., M.Sc., Mary Lee Krinsky, D.O., and Denise Kalmaz, M.D.. There are also two advanced endoscopy fellows for 2011-2012, Dr. Ingrid Gonzalez (Harvard/MGH Internal Medicine Residency and UCSD GI Fellowship), and Dr. Craig Munroe (Harvard/MGH Internal Medicine Residency and Stanford GI Fellowship). Services are provided at UCSD Thornton Medical Center, as well as UCSD Hillcrest Medical Center and the VA Medical Center La Jolla. Advanced endoscopic procedures include EUS for diagnosis, staging, and treatment, ERCP (including cholangioscopy) for biliary stone removal and stent placement, endoscopic treatment of Barrett’s esophagus and early esophageal cancer, endoscopic management of complicated colon polyps, and capsule endoscopy and double balloon enteroscopy to evaluate the small intestine for bleeding sites and possible tumors.

Clinical research activity in recent years has focused on developing and evaluating EUS FNA for diagnosing lung cancer, performance quality benchmarks for EUS FNA of pancreatic masses. EUS techniques to place metal markers (fiducials) into tumors to allow stereotactic radiosurgery, performance techniques for quality colon cancer screening with colonoscopy, endoscopic mucosal resection of gastric antral pancreatic rests, and missed work related to screening colonoscopy. Current research is focused on the natural history of incidentally found small pancreatic cysts, use of capsule endoscopy instead of upper endoscopy prior to bariatric surgery, and cholangitis development in patients with pancreatic cancer and metal biliary stents.

Our collaboration with the UCSD Minimally Invasive Surgery Program, directed by Dr. Santiago Horgan, has been especially exciting. We have helped Dr. Horgan develop UCSD as one of the leading centers in the world for Natural Orifice Translumenal Endoscopy Surgery. This involves removing the gallbladder and appendix through natural orifices, such as the stomach or vagina. We have also pioneered important novel combined endoscopic and laparoscopic procedures, such as endoscopic/laparoscopic management of acute esophageal perforations, trans-gastric endoscopic/laparoscopic resection of gastrointestinal stromal cell tumors (GISTs), and laparoscopic-assisted ERCP in patients with prior Roux-en-Y gastric bypass. Most recently we have become one of the only centers in the United States to use a novel over the scope endoscopic clip to close chronic gastric, esophageal, and colonic fistulas. With the opening of the UCSD Center for the Future of Surgery, UCSD will be one of the largest endoscopic and laparoscopic training centers in the country.

Patient referrals for the UCSD Advanced Endoscopy Program can be made by calling 858-657-6882 or faxing relevant information to 858-657-6881.
EAST CAMPUS OFFICE BUILDING (ECOB)

We are very excited for the move to our new installations, the East Campus Building will be the official home of our divisional business office and will be host several of our clinicians, coordinators and members of our administrative staff. ECOB is comprised of 3 floors and will house over three-hundred faculty and staff from several other divisions.

Our presence at UC 303 will remain strong as this will remain the home for several of our researchers, and laboratory staff who will be supported by our administrative assistant, Olivia Hernandez.

MEDICAL EDUCATION & TELEMEDICINE BUILDING

In addition to the new space at ECOB we will also have access to the new Medical Education & TeleMedicine Building, as the name implies this building will include space to be used by several training programs including endoscopy training.

For more information on this building please go to: http://telemedicine.ucsd.edu

AWARDS & RECOGNITIONS

- Congratulations to Dr. Ravinder Mittal, his RO1 on the “Morphology of External Anal Sphincter Assessed with Novel Magnetic Resonance Imaging” recently received a 6th percentile score and was granted funding. In addition, a research abstract on external anal sphincter morphology won the Best Basic Science Award, among more than 1000 abstracts they received at the International Continence Society meeting in Glasgow, UK. Dr. Mittal also gave a state of the art lecture entitled, "Link between Longitudinal Muscles of Esophagus with Chest Pain and Heartburn" at Neurogastroenterology Meeting in Saint Louise in September 2011.

- The American Gastroenterological Association recently invited Dr. Sheila Crowe to join the AGA Academy of GI and Liver Educators as a charter member. As a leading expert on Celiac Disease, Dr. Crowe, was recently featured in Self Magazine, the article focused on the benefits of a gluten-free diet. You may view a transcript of the full interview by clicking on the following link: http://www.self.com/fooddiet/2011/10/giving-up-gluten

- The W. K. Warren Medical Research Center for Celiac Disease together with participation of San Diego’s Celiac Disease Support Groups is co-sponsoring a Gluten Free Food Expo for the San Diego Community at the Scottish Rite Center in Mission Valley on Nov. 12 from 1pm to 4pm. All proceeds go to the Warren Center for clinical research and community outreach programs. Come and sample gluten free products from over 50 vendors. For more information go to: http://celiaccenter.ucsd.edu or http://sdgfexpo.com/
...AWARDS & RECOGNITIONS

- **Dr. Thomas Savides** was recently recognized among US News and World Report 2011 “Top Doctors” List. In addition, San Diego Magazine has also listed Dr. Savides as a “Best Doctor” in Gastroenterology, this is not the first time that such a recognition has been awarded to Dr. Savides, we are extremely proud of his achievements. For a complete list of UCSD affiliated awardees please go to:http://med.ucsd.edu/USTopDocs2011.shtml

- **Drs. Robert Gish & Alan Hemming** made national news as UCSD’s C.H.A.T. program was the first of its kind to successfully perform a domino transplant using one liver and potentially saving the lives of two patients. More information can be found at: http://ucsdnews.ucsd.edu/newsrelhealth/2011_09hemming gish.asp

- **Dr. John Chang** was recently awarded a 2011 NIH Director’s New Innovator Award to study fundamental mechanisms by which cell fate is determined during immune responses against microbes. Dr. Chang’s research group will receive $2.3 million over the next five years for the study. Dr. Chang was among 49 scientists nationwide to receive the prestigious award this year, which funds research projects “that challenge the status quo with innovative ideas that have the potential to propel fields forward and speed the translation of research into improved health for the American public.” The study could have implications for improved vaccine strategies and suggest new treatments for inflammatory bowel disease. More information about the New Innovator Award and the 2011 awardees is available at: http://commonfund.nih.gov/newinnovator/

- The NIH/NIAAA has awarded **Dr. Bernd Schnabl** an RO1 award for a project entitled "Microbiome and intestinal innate immune response in alcoholic liver disease". The focus of this application is to characterize the relationship between alcohol, the intestinal innate immune system and changes in the intestinal microflora.

- The Executive Vice-Chancellor has announced **Dr. Kim Barrett’s** reappointment as Dean of Graduate Studies for an additional five-year term. Dean Barrett has provided outstanding leadership to the campus in her capacity as Dean of Graduate Studies. We are pleased to have her as part of our division.

RECENT PUBLICATIONS


Cohen B, Docherty MJ. Combination Therapy for Crohn’s Disease: A Survey of Physician Practice Patterns[abstract]. In: ACG Annual Scientific Meeting; 2011 Oct 28-Nov 2; Washington, DC.


RECENT PUBLICATIONS...CONT'D


Making the most of your charitable gifts before December 31st

It’s that time of year again. As you think about special holiday gifts for family and friends, remember that making year-end charitable gifts can be a rewarding experience. Here are just a few options to support the UC San Diego Division of Gastroenterology:

**Option 1** – The simplest way to donate is a gift of cash (including checks and credit cards). Remember if you itemize you may be able to receive a charitable deduction for 2011 for your gifts received on or before December 31st.

**Option 2** – A gift of appreciated securities also offers an attractive opportunity to support the Division of Gastroenterology. By contributing appreciated securities that you have held longer than 12 months, you will receive a charitable income tax deduction, in most cases for their full fair market value, and avoid any capital gains tax liability. It is important to remember that your securities must be transferred to the U.C. San Diego Foundation by December 31st for the 2011 tax year. You will receive a charitable deduction for 2011 for your gifts received on or before December 31st.

**Option 3** – IRA Rollover – If you are 70 ½ years or older and the owner of an Individual Retirement Account (IRA) you might consider a rollover gift of up to $100,000 to the UC San Diego Foundation in support of Division of Gastroenterology. While no charitable deduction accompanies the transfer, the distribution directly to the charity is not included as part of your taxable income. Gifts must be completed by December 31, 2011.

**Option 4** – Name the Division of Gastroenterology at the UC San Diego Foundation in your will or trust. While you may not receive an immediate charitable deduction, you will have the satisfaction of sustaining and enhancing the future of the division.

We’re here to help you make the most of your year-end gifts. For more information about any of the options listed please contact Harvey Green, Director of Development, at (619) 543-3121 or hagreen@ucsd.edu. Also, for information about planned gifts or bequests visit www.giftplanning.ucsd.edu.

Please note that this information is educational purposes only. The UCSD office of development and gift planning is not engaged in rendering tax or legal advice. As you consider charitable gifts, we strongly encourage you to consult with your own attorney, CPA and/or other financial advisors as needed. UC San Diego Foundation Tax ID # 95-2872494 in compliance with 501(c)3 status.
Organization Statement

The UCSD GI Division will provide the best clinical care to those afflicted with gastrointestinal and liver diseases, investigate at the clinical and basic levels the best way to improve those diseases, and educate trainees on how to best approach the care of patients with those diseases. The UCSD GI Division will strive to be nationally recognized through its faculty as well as innovations that will improve the care of patients with gastrointestinal and liver diseases nationwide.

The UCSD GI Division was founded in 1970 by Henry Wheeler, M.D. who served as its first Division Chief. Later, Jon I. Isenberg, M.D. led the Division from 1979 to 1993, followed by C. Richard Boland, M.D. from 1995 to 2003, John M. Carethers, M.D., from 2004 - 2009 and William J. Sandborn from 2011-Present. The GI fellowship Training Program commenced in 1974 and the NIH Training Grant was initially funded in 1976. The Division has trained several local gastroenterologists in San Diego, as well as developed several academicians at University-based medical schools, including some with leadership and administrative positions.
Postgraduate Courses:

Saturday 10/29

Session 1A: Upper Gut
Moderator: Joel E. Richter, Md, MACG
8:40 am Celiac Disease: When to Look and How? Sheila E. Crowe, MD, FACG
Create a practical approach to clinical scenarios where celiac disease should be suspected and decide the needed tests to confirm or rule it out.

Saturday Learning Luncheons
12:20 pm – 1:35 pm
Recent Developments in and Applications of Endoscopic Ultrasound
Thomas J. Savides, MD
Update the clinician about recent developments and applications of endoscopic ultrasound.

Tuesday 11/01

Plenary Session 1: Outcomes / IBD
MODERATORS: Paul Moayyedi, MD
Stephen B. Hanauer, MD, FACG

20. Malignancy in Patients with Crohn’s Disease: Data from the TREAT™ Registry with More than 5 Years of Follow-up
Gary Lichtenstein, MD, FACG, Brian Feagan, MD, R. Cohen, MD, B. Salzberg, MD, R. Diamond, MD, W. Langhoff, PhD, A. Londhe, PhD, William Sandborn, MD, FACG, University of Pennsylvania School of Medicine, Philadelphia, PA; Roberts Research Institute, London, Ontario, Canada; University of Chicago Medical Center, Chicago, IL; Atlanta Gastroenterology Associates, Atlanta, GA; Centocor Ortho Biotech Services, LLC, Horsham, PA; Ovation Research Group, Highland Park, IL; Johnson & Johnson PRD, Edison, NJ; University of California San Diego, La Jolla, CA

Wednesday 11/02

6:45 am–8:15 am
OPTIONAL Breakfast Sessions

Breakfast O: The Food We Eat – Nourishment or Punishment?
Assess the significance of food allergies in the management of patients with gastrointestinal symptoms; differentiate between true celiac disease and symptoms associated with ingestion of gluten; and demonstrate the association between the gut microflora and obesity.

Moderator: John K. DiBaise, MD, FACG

1. Food Allergies – Can We Ever Eat a Peanut Again? Sheila E. Crowe, MD, FACG

2. Celiac Disease vs. Gluten Intolerance
Joseph A. Murray, MD, FACG

3. Guts, Microbes and Obesity– What’s the Connection?
John K. DiBaise, MD, FACG

25. Derivation of a Microscopic Colitis Disease Activity Index (MCDAI)
Darrell Pardi, MD, MS, FACG, Rami Abboud, MD, Meredith Mc-Nally, MD, William Tremaine, MD, William Sandborn, MD, FACG, Patricia Kammer, W. Scott Harmsen, MS, Alan Zinsmeister, PhD, Edward Loftus, MD, FACG, Mayo Clinic, Rochester, MN; Cleveland Clinic, Cleveland, OH; University of California, San Diego, CA

ACG GI JEOPARDY FINALS: SATURDAY OCTOBER 29, 2011 @ 5:15PM—Maryland Ballroom C
UCSD GI is honored to be represented by 3 exceptional fellows: Drs. Suresh Pola, Thuy Anh Le and Imad Elkhatib.
**Wednesday 11/02**

**Plenary Session 1: IBD / Functional**

**MODERATORS:**
Richard P. MacDermott, MD, MACG
William D. Chey, MD, FACG

**57. Adalimumab Therapy Reduces Hospitalization and Colectomy Rates in Patients with Ulcerative Colitis: Data from Controlled Trials**
Brian Feagan, MD, FACC, William Sandborn, MD, FACC, Mei Yang, PhD, Kathleen Lomax, MD, Andreas Lazar, MD, Roopal Thakkar, MD, Parvez Mulani, PhD, Jingdong Chao, PhD, Robarts Research Institute, University of Western Ontario, London, Ontario, Canada; University of California, San Diego, La Jolla, CA; Abbott Laboratories, Abbott Park, IL

**Simultaneous Symposia**

**5B: Biologics 101 – Learn with the Experts: A Case Based Symposia**

Define important parameters used in the management and treatment of patients with IBD. Determine optimization strategies for use of anti-TNF therapy and assess when to start and stop biologics.

**Moderator:**
Gary R. Lichtenstein, MD, FACC

1. When to Start Biologics
Gary R. Lichtenstein, MD, FACC

2. Optimization of Biologics
William J. Sandborn, MD, FACC

3. Can We Stop Biologics?
Brian G. Feagan, MD, FACC

---

**POSTER SESSIONS**

**Sunday 10/30**
3:30-7:00pm

**INFLAMMATORY BOWEL DISEASE**

**P279. Elevated C-reactive Protein in Anti-TNF-Naïve Patients Is Associated with Higher Remission Rates**
William Sandborn, MD, Jean-Frederic Colombel, MD, Majin Castillo, MD, Qian Zhou, PhD, Roopal Thakkar, MD, University of California San Diego, La Jolla, CA, Centre Hospitalier Universitaire de Lille, Lille, France, Abbott, Abbott Park, IL

**P280. Baseline C-reactive Protein (CRP) and Plasma Anti-TNF Concentration in Patients with Active Crohn’s Disease Treated with Certolizumab Pegol (CZP)**
William Sandborn, MD, Brian Feagan, MD, Scott Lee, MD, David Binion, MD, Edward Loftus, MD, Bosny Pierre-Louis, DrPH, Thomas Ullman, MD, University of California, San Diego, La Jolla, CA, Robarts Research Institute, University of Western Ontario, London, ON, University of Washington School of Medicine, Seattle, WA, University of Pittsburgh, Pittsburgh, PA, Mayo Clinic, Rochester, MN, UCB Inc, Raleigh, NC, Mount Sinai Medical Center, New York, NY

**P281. Association of Baseline C-Reactive Protein with Maintenance of Remission in Patients with Moderate to Severe Crohn’s Disease Treated with Adalimumab**
William Sandborn, MD, Jean-Frederic Colombel, MD, Anne Robinson, PharmD, Paul Pollack, MD, Qian Zhou, PhD, Roopal Thakkar, MD, University of California San Diego, La Jolla, CA, Centre Hospitalier Universitaire de Lille, Lille, France, Abbott, Abbott Park, IL
P706. Low Risk of Pneumocystis jirovecii Pneumonia in Patients with IBD Receiving Chronic Corticosteroid Therapy Does Not Justify Prophylaxis: A Population Based Study  

Nicola Gathaiya, MBBS, Jelena Catania, MD, Edward Loftus, MD, William Sandborn, MD, William Tremaine, MD, Larry Baddour, MD, Andrew Limper, MD, Darrell Pardi, MD, Mayo Clinic, Rochester, MN, UC San Diego, La Jolla, CA, Duke University, Durham, NC

P711. Fecal Calprotectin Concentration and Clinical Response to Certolizumab Pegol in Patients with Active Crohn’s Disease: Results from PRECISE 2  

William Sandborn, MD, Bosny Pierre-Louis, DrPH, Thomas Ullman, MD, David Binion, MD, University of California San Diego, La Jolla, CA, UCB Inc, Raleigh, NC, Mount Sinai Medical Center, New York, NY, University of Pittsburgh, Pittsburgh, PA

P712. Inflammatory Biomarkers and Clinical Remission in Patients with Active Crohn’s Disease: Results from PRECISE 2  

William Sandborn, MD, Thomas Ullman, MD, Bosny Pierre-Louis, DrPH, David Binion, MD, University of California San Diego, La Jolla, CA, Mount Sinai Medical Center, New York, NY, UCB Inc, Raleigh, NC, University of Pittsburgh, Pittsburgh, PA

P713. Antibodies Against Certolizumab Pegol (CZP), Plasma Concentrations of CZP and Efficacy in Patients with Crohn’s Disease Receiving Continuous CZP Therapy with or without Concomitant Immunosuppressants  

William Sandborn, MD, David Binion, MD, David Rubin, MD, Thomas Ullman, MD, Bosny Pierre-Louis, Edward Loftus, MD, University of California San Diego, La Jolla, CA, University of Pittsburgh, Pittsburgh, PA, University of Chicago Medical Center, Chicago, IL, Mount Sinai Medical Center, New York, NY, UCB Inc, Raleigh, NC, Mayo Clinic, Rochester, MN

P714. Sustained Clinical Remission of Ulcerative Colitis Is Associated with Greater Improvements in Quality of Life, Work Productivity and Activity  

William Sandborn, MD, Jean-Frederic Colombel, MD, Mei Yang, PhD, Roopal Thakkar, MD, Parvez Mulani, PhD, Jingdong Chao, PhD, University of California, San Diego, La Jolla, CA, Centre Hospitalier Universitaire de Lille, Lille, France, Abbott Laboratories, Abbott Park, IL

P731. Baseline C-Reactive Protein is Associated with Disease Progression in Patients with Crohn’s Disease  

Jean-Frederic Colombel, MD, William Sandborn, MD, Majin Castillo, MD, Bidang Huang, PhD, Qian Zhou, PhD, Roopal Thakkar, MD, Hospitalier Universitaire de Lille, Lille, France, University of California San Diego, La Jolla, CA, Abbott, Abbott Park, IL

P733. Efficacy and Safety of Adalimumab in Moderate to Severe Crohn’s Disease: Pooled Data from the CHARM and EXTEND Trials  

Jean-Frederic Colombel, MD, William Sandborn, MD, Majin Castillo, MD, Qian Zhou, PhD, Roopal Thakkar, MD, Centre Hospitalier Universitaire de Lille, Lille, France, University of California San Diego, La Jolla, CA, Abbott, Abbott Park, IL

P738. Pouchitis and Other Pouch Dysfunction Syndromes after ileal Pouch-Anal Anastomosis for Ulcerative Colitis or Indeterminate Colitis: A Population-Based Study  

2011 ACG IBD Abstract Award Recipient  

Rohit Singhania, MBBS, SM, Darrell Pardi, MD, William Tremaine, MD, Sunanda Kane, MD, David Bruining, MD, William Sandborn, MD, Patricia Kammer, CCRP, Kammers, CCRP, W. Scott Harmsen, MS, Alan Zinsmeister, PhD, Edward Loftus, MD, St. Lukes Roosevelt Hospital, New York, NY, Mayo Clinic, Rochester, MN

P1040. The Association of Serologic Inflammatory Markers with Microscopic Colitis Disease Activity  

Ramiel Abboud, MBBS, Darrell Pardi, MD, William Tremaine, MD, William Sandborn, MD, Patricia Kammer, CCRP, Edward Loftus, MD, Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, University of California San Diego, San Diego, CA

P1133. Induction of Clinical and Endoscopic Remission of Mild to Moderately Active Ulcerative Colitis with Budesonide MMX® 9 mg: Analysis of Pooled Data from Two Phase 3 Studies  

William Sandborn, MD, Simon Travis, MD, Natarajan Bala, MD, Silvio Danese, MD, Luigi Moro, MD, E. David Ballard, MD, Therese Gauvitate, RN, Bob Bagin, PhD, Michael Huang, MD, UC San Diego, San Diego, CA, John Radcliffe Hospital, Oxford, United Kingdom, GI Consultants, P.A., Houston, TX, Instituto Clinico Humanitas, Milan, Italy, Cosmo Pharmaceuticals, Lainate, Italy, Santaros, San Diego, CA

P1134. Sustained Remission with No Dose Escalation after Re-induction with Certolizumab Pegol in Patients with Crohn’s Disease Exacerbation: 1-Year Results from PRECISE 4  

William Sandborn, MD, David Rubin, MD, David Sen, PhD, Brian Feagan, MD, University of California, San Diego, La Jolla, CA, University of Chicago Medical Center, Chicago, IL, UCB Inc, Raleigh, NC, Roberts Research Institute, University of Western Ontario, London, ON

P1135. Target Mediated Disposition (TMD) Model Based Dose Selection for Fixed SC Doses of Anti-MAdCAM-1 Monoclonal Antibody (PF-00547659) in Crohn’s Disease  

William Sandborn, MD, Jason Williams, PhD, Fabio Cataldi, MD, Gail Comer, MD, University of California San Diego, La Jolla, CA, Pfizer Inc., Collegeville, PA, Pfizer, Cambridge, MA
P1136. Induction of Remission with Adalimumab in Patients with Moderate Crohn’s Disease: Subanalysis of CLASSIC I
William Sandborn, MD, Jean-Frederic Colombel, MD, Majin Castillo, MD, Qian Zhou, PhD, Roopal Thakkar, MD, University of California San Diego, La Jolla, CA, Centre Hospitalier Universitaire de Lille, Lille, France, Abbott, Abbott Park, IL

P1137. Combination Therapy for Crohn’s Disease: A Survey of Physician Practice Patterns
Michael Docherty, MD, Benjamin Cohen, MD, UCSD Medical Center, La Jolla, CA